Repro Med Systems Inc (REPR)

[blue_skies]

FDA Approves Xembify (immune globulin subcutaneous) for Primary Immunodeficiencies


Barcelona, July 4, 2019.- Grifols, a leading global producer of plasma-derived medicines, announced today that Xembify, its new 20% subcutaneous immunoglobulin, has been approved by the U.S. Food and Drug Administration (FDA). Xembify is used to treat primary immunodeficiencies

RMS has partnered with Grifols to provide the pumps. This is a validation of the RMS strategy of partnering with drug companies as they introduce Sub Q therapies. The revenue stream from this partnership looks to start by the end of the year.

https://www.drugs.com/newdrugs/fda-approves-xembify-immune-globulin-subcutaneous-primary-immunodeficiencies-5012.html?utm_source=ddc&utm_medium=rss&utm_campaign=FDA+Approves+Xembify+%28immune+globulin+subcutaneous%29+for+Primary+Immunodeficiencies